Stockscreener 앱 받기
2.10
4.11%
-0.09
시간 외 거래:
2.05
-0.05
-2.38%
iBio Inc 주식(IBIO)의 최신 뉴스
IBIO: Analyst Keay Nakae Reaffirms 'Buy' Rating with $5.00 Price Target | IBIO Stock News - GuruFocus
Aug Opening: How do insiders feel about iBio IncQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion - Investing.com
VIX Spike: Is IBIO in a long term uptrend2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
iBio (NASDAQ:IBIO) Given Buy Rating at Chardan Capital - MarketBeat
iBio (IBIO) to Discuss Pipeline Expansion in Upcoming Conference Call - GuruFocus
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - The Manila Times
Stop Loss: How sensitive is iBio Inc to inflationWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
iBio to Provide an Update on Cardiopulmonary Program - GlobeNewswire
iBio reports fat reduction in primate obesity study By Investing.com - Investing.com Nigeria
Ibio SEC Filings - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Highs Report: Is iBio Inc a turnaround storyRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
IBIO: Advancing novel antibody therapies for obesity and cardiometabolic disease with strong clinical momentum - TradingView
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1 - Minichart
IBIO: Innovative antibody pipeline aims for fat-specific weight loss and muscle preservation in obesity - TradingView
iBio reports fat reduction in primate obesity study - Investing.com India
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential - TipRanks
iBio (IBIO) Reports Promising Preclinical Results for Obesity Tr - GuruFocus
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - Bitget
Primate obesity study backs iBio fat-loss antibody, twice-yearly dosing potential - Stock Titan
[EFFECT] iBio, Inc. SEC Filing - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Cash per share of iBio, Inc. – MUN:0JV0 - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com Australia
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
Revenue per share of iBio, Inc. – MUN:0JV0 - TradingView
Ibio Ends At-The-Market Equity Offering Program - The Globe and Mail
iBio (NASDAQ:IBIO) Raised to Hold at Wall Street Zen - MarketBeat
IBio enters open market sale agreement with Jefferies - marketscreener.com
IBio Files $200 Million Mixed Shelf Offering - marketscreener.com
iBio Launches Up to $100 Million ATM Program With Jefferies to Bolster Liquidity - TradingView
iBio (NYSE: IBIO) launches $100M at-the-market stock offering with Jefferies - Stock Titan
IBio Inc files for mixed shelf of up to $200 million - marketscreener.com
iBio Inc Files For Mixed Shelf Of Upto $200 Million - TradingView
Ken Johnson - Crain's Chicago Business
IBIO: Pipeline advances in obesity and cardiovascular drugs with strong financial backing and near-term data - TradingView
IBIO: Advancing next-gen obesity therapies with strong financials and key data readouts ahead - TradingView
Growth Report: Will iBio Inc benefit from green energy policiesMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Aug Selloffs: Is Beazer Homes USA Inc forming a breakout patternTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
iBio (NYSEMKT:IBIO) Stock Price Up 2.9%Should You Buy? - MarketBeat
How do insiders feel about iBio Inc.Rate Cut & Step-by-Step Swing Trade Plans - mfd.ru
iBio to Participate in Upcoming Investor Conferences - The Manila Times
iBio leaders join fireside chats at Oppenheimer and Leerink healthcare events - Stock Titan
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
IBio, Inc. (IBIO) Stock: Price Predictions & Analysis - thedetroitbureau.com
ADAR1 discloses 4.4% iBio (IBIO) ownership in updated 13G filing - Stock Titan
Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO) - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):